Protective efficacy of the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanese children.
The clinical efficacy of an acellular pertussis vaccine containing lymphocytosis-promoting factor, filamentous hemagglutinin, agglutinogens, and the 69-kd outer membrane protein, combined with diphtheria and tetanus toxoids and adsorbed onto an aluminum salt, was assessed in a household contact study. The occurrence of pertussis 7 to 30 days following home exposure among 62 previously vaccinated children was compared with that among 62 unvaccinated children similarly exposed. Classic whooping cough was diagnosed in 43 unimmunized children, and 1 vaccinated child experienced a 5-week illness that was probably pertussis (efficacy, 98%; 95% confidence interval, 84% to 99%). A few children in each group incurred respiratory illnesses that may have represented mild, atypical pertussis; including these as probable pertussis, vaccine efficacy was 81% (95% confidence interval, 64% to 90%). It is concluded that prior immunization with this four-component pertussis vaccine combined with diphtheria and tetanus toxoids is highly efficacious in preventing pertussis.
Mortimer
E A
EA
Department of Epidemiology, Case Western Reserve University, Cleveland, Ohio.
Kimura
M
M
Cherry
J D
JD
Kuno-Sakai
H
H
Stout
M G
MG
Dekker
C L
CL
Hayashi
R
R
Miyamoto
Y
Y
Scott
J V
JV
Aoyama
T
T
D015982:Bias; D002648:Child; D002675:Child, Preschool; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage / Q000494:pharmacology / Q000592:standards*; D006801:Humans; D007223:Infant; D007564:Japan; D014917:Whooping Cough / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*
D015721:Diphtheria-Tetanus-Pertussis Vaccine